Imagine a 3D printer that works directly inside the body during surgery instead of in a lab. It uses lasers to precisely place a patient's own cells exactly where they are needed to fix damaged organs. For example, it can rebuild a bladder lining using the patient's own cells, avoiding the complications of using intestinal tissue as a substitute.
Current bladder reconstruction often uses intestinal tissue, which causes mucus secretion, metabolic defects, and kidney stones. There is a lack of tools to precisely place autologous cells directly into the body during surgery.
A compact, automated laser bioprinter using LIFT technology and a set of protocols for cell isolation, expansion, and in-vivo printing.
If you are a surgical robotics firm dealing with the limitations of static implants — this project developed a compact laser bioprinter that allows for real-time tissue engineering during operations. This enables the creation of hybrid tissues with autologous characteristics directly in the surgery room.
If you are a urology clinic dealing with the side-effects of intestinal epithelium in neobladder surgery — this project developed a tool to print urothelial lining. This eliminates the need for intravesical washings to remove mucus and reduces stone formation risk.
If you are a cell therapy provider dealing with the challenge of delivering expanded cells to a precise surgical site — this project developed protocols for cell isolation and expansion paired with a high-speed LIFT printing device. This ensures cells are placed with high precision in-vivo.
Based on available project data, specific pricing for the D-LIB platform is not disclosed, though the technology is described as cost-effective due to the LIFT technique.
The project has already produced two fully functional bioprinters, including an upgraded version for first-in-human clinical trials, indicating a transition toward industrial-grade medical devices.
The technology is protected by 5 patent families and additional trade secrets.
PhosPrint established a Quality Management System (QMS) with a US-based consulting company to comply with both EMA and FDA requirements.
The project period runs from 2023-05-01 to 2026-04-30, with an upgraded device currently intended for first-in-human clinical trials.
The project is led by a single SME, PhosPrint ANONYMI ETAIREIA, representing a 100% industry ratio. This lean structure suggests a highly focused commercial drive, with the SME managing everything from IP (5 patent families) to regulatory QMS implementation for FDA/EMA compliance.
Contact PHOSPRINT ANONYMI ETAIREIA in Greece regarding D-LIB platform licensing.
Contact us to explore partnership opportunities with PhosPrint for in-vivo bioprinting applications.
